Navigation Links
Delcath Systems, Inc. Secures $20 Million Credit Facility
Date:4/23/2012

w hemofiltration cartridge,  the timing of the supply and distribution of the CHEMOSAT system including the new hemofiltration cartridge to early launch centers Europe,  the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.Contact Informa
'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... BIRMINGHAM, Ala., June 8, 2011 SANYO North ... its Cell Processing Work Station (CPWS), an integrated, stand-alone ... stem cell and cell therapies for research use, has ... (UAB) as the nation,s first installation of the CPWS, ...
... 2011 According to a report published today by ... has begun to adapt to stricter governmental brand name ... it files for every new drug. These newer standards ... European Medicines Agency (EMA) are part of an effort ...
Cached Medicine Technology:SANYO Installs First Cell Processing Work Station in the United States at University of Alabama at Birmingham 2SANYO Installs First Cell Processing Work Station in the United States at University of Alabama at Birmingham 3Thomson Reuters Trademark Report Reveals New Challenges and Opportunities for Pharmaceutical Brands 2Thomson Reuters Trademark Report Reveals New Challenges and Opportunities for Pharmaceutical Brands 3
(Date:4/20/2014)... Calif. A single type of cell in the ... of invasive bladder cancer, according to researchers at the ... in mice, is the first to pinpoint the normal ... cancers. It,s also the first to show that most ... just one cell, and explains why many human bladder ...
(Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
(Date:4/18/2014)... is available in French . ... surgical practice and regenerative medicine. A team led by ... (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire ... has just demonstrated that the principle of adhesion by ... to repair soft-tissue organs and tissues. This easy-to-use gluing ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2
... Businesses Encouraged to Reduce Air Pollution, HARRISBURG, ... and its regional air quality partnerships have,forecast an ... in the,Berks/Lehigh, Liberty/Clairton, Philadelphia, Pittsburgh and Susquehanna,Valley regions., ... be code ORANGE for,ozone in the Berks/Lehigh Valley, ...
... brain are lost through disease or injury, neighboring cells begin ... the brain are able to produce new neurons. Patients with ... an area of the brain called the substantia nigra and ... these areas have not been well described because of limitations ...
... family reunion in Arkansas. The nurse and the research coordinator at The ... going West in search of the serum that binds this family. More ... ... Christine Demers and Areeba Sadiq set off for a family reunion in ...
... Program Encourages Kids to ,Eat Smart for a Great Start, ... ... ,Produce for Kids(R) (PFK), an organization that promotes the benefits of,healthy eating ... and tools that support the positive,development of the whole child - the ...
... N.J., Sept. 3 Teva,Pharmaceutical Industries Ltd. (Nasdaq: ... BRL ) announced today that, as expected, each ... referred to as a "second,request") from the U.S. ... acquisition of Barr. The parties have been cooperating ...
... 3 Z Trim Holdings,Inc. (Amex: ZTM ) issued ... September 3, 2008, To: Z Trim Shareholders, ... In this second installment of periodic updates intended to ... on the motives and,outcomes -- realized and anticipated -- behind ...
Cached Medicine News:Health News:Air Quality Action Day Forecast Thursday in All Regions 2Health News:New methods identify and manipulate 'newborn' cells in animal model of Parkinson's disease 2Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 2Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 3Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 4Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 5Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 2Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 3Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 4Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 5Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 6Health News:Teva and Barr Receive FTC Request for Additional Information 2Health News:Teva and Barr Receive FTC Request for Additional Information 3Health News:Teva and Barr Receive FTC Request for Additional Information 4Health News:Teva and Barr Receive FTC Request for Additional Information 5Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 2Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 3Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 4Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 5Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 6
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
A low viscosity type of bone cement, intended for syringe or cement gun application....
Antibiotics (Gentamicin) loaded, low viscosity bone cement for syringe use with an average setting time of approx. 7-9 Min., 41.6g of powder and 16.4g of liquid....
Medicine Products: